FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)


NCT01328171

Interventional

Phase 2

Active, not recruiting
VOLFI
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer of RAS wildtype. The patients will be treated in two therapy groups: Experimental arm A: Chemotherapy with FOLFOXIRI + panitumumab Standard arm B: Chemotherapy with FOLFOXIRI
Apr 30,2011
All
18 Years
N/A
93

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.